Journal Article

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

Huang, He, Jiang, Er-lie, Lai, Yong-rong, Ren, Han-yun, Song, Yong-Ping, Xu, Lan-ping, Zhang, Xi, Tang, Xiao-wen, Jiang, Ming, Han, Ming-Zhe, Wang, Jian-min, Liu, Dai-hong, Zhang, Xiao-hui, Zhou, Dao-bin, Huang, Xiao-jun, Wu, De-pei, Chen, Jing, Liu, Qi-Fa, Liu, Ting, Sun, Zi-min

2021

Overview

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization of clinical practices of allo-HSCT in China and progressive integration with the world. There have been new developments since the initial publication. To integrate recent developments and further improve the consensus, a panel of experts from the CSH recently updated the consensus recommendations, which are summarized as follows: (1) there is a new algorithm for selecting appropriate donors for allo-HSCT candidates. Haploidentical donors (HIDs) are the preferred donor choice over matched sibling donors (MSDs) for patients with high-risk leukemia or elderly patients with young offspring donors in experienced centers. This replaces the previous algorithm for donor selection, which favored MSDs over HIDs. (2) Patients with refractory/relapsed lymphoblastic malignancies are now encouraged to undergo salvage treatment with novel immunotherapies prior to HSCT. (3) The consensus has been updated to reflect additional evidence for the application of allo-HSCT in specific groups of patients with hematological malignancies (intermediate-risk acute myeloid leukemia (AML), favorable-risk AML with positive minimal residual disease, and standard-risk acute lymphoblastic leukemia). (4) The consensus has been updated to reflect additional evidence for the application of HSCT in patients with nonmalignant diseases, such as severe aplastic anemia and inherited diseases. (5) The consensus has been updated to reflect additional evidence for the administration of anti-thymocyte globulin, granulocyte colony-stimulating factors and post-transplantation cyclophosphamide in HID-HSCT.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Acute lymphoblastic leukemia / Acute myeloid leukemia / Algorithms / Allogeneic hematopoietic transplantation / Antithymocyte globulin / Aplastic anemia / Cancer Research / Chemotherapy / China / China - epidemiology / Colony-stimulating factor / Conditioning regimen / Consensus / Cyclophosphamide / Disease / Donor selection / Donor Selection - methods / Donors / Globulins / Hematologic Neoplasms - epidemiology / Hematologic Neoplasms - therapy / Hematology / Hematopoietic Stem Cell Transplantation - methods / Hematopoietic stem cells / Hereditary diseases / Humans / Immunotherapy / Indication / Leukemia / Leukemia, Myeloid, Acute - epidemiology / Leukemia, Myeloid, Acute - therapy / Leukocytes (granulocytic) / Lymphatic leukemia / Medical prognosis / Medicine / Medicine & Public Health / Minimal residual disease / Mortality / Mutation / Myeloid leukemia / Oncology / Patients / Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology / Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy / Remission (Medicine) / Review / Societies, Medical / Standardization / Stem cell transplantation / Stem cells / Thymocytes / Trade and professional associations / Transplantation / Transplantation Conditioning - methods / Transplantation, Homologous - methods